EA020579B1 - Способ лечения реперфузионных повреждений тканей - Google Patents

Способ лечения реперфузионных повреждений тканей Download PDF

Info

Publication number
EA020579B1
EA020579B1 EA201170294A EA201170294A EA020579B1 EA 020579 B1 EA020579 B1 EA 020579B1 EA 201170294 A EA201170294 A EA 201170294A EA 201170294 A EA201170294 A EA 201170294A EA 020579 B1 EA020579 B1 EA 020579B1
Authority
EA
Eurasian Patent Office
Prior art keywords
zeg
azp
azr
bie
reperfusion
Prior art date
Application number
EA201170294A
Other languages
English (en)
Russian (ru)
Other versions
EA201170294A1 (ru
Inventor
Андрей В. Гудков
Роберт Фэйрчайлд
Original Assignee
Кливленд Байолэбс, Инк.
Кливленд Клиник Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кливленд Байолэбс, Инк., Кливленд Клиник Фаундейшн filed Critical Кливленд Байолэбс, Инк.
Publication of EA201170294A1 publication Critical patent/EA201170294A1/ru
Publication of EA020579B1 publication Critical patent/EA020579B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EA201170294A 2008-08-01 2009-07-31 Способ лечения реперфузионных повреждений тканей EA020579B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8576608P 2008-08-01 2008-08-01
PCT/US2009/052493 WO2010014957A1 (en) 2008-08-01 2009-07-31 Methods for treating reperfusion injuries

Publications (2)

Publication Number Publication Date
EA201170294A1 EA201170294A1 (ru) 2011-08-30
EA020579B1 true EA020579B1 (ru) 2014-12-30

Family

ID=41610763

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170294A EA020579B1 (ru) 2008-08-01 2009-07-31 Способ лечения реперфузионных повреждений тканей

Country Status (10)

Country Link
US (4) US8324163B2 (https=)
EP (1) EP2320948B1 (https=)
JP (1) JP5577337B2 (https=)
CN (1) CN102170911B (https=)
AU (1) AU2009276357B2 (https=)
CA (1) CA2732763A1 (https=)
EA (1) EA020579B1 (https=)
ES (1) ES2412237T3 (https=)
PT (1) PT2320948E (https=)
WO (1) WO2010014957A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795656C2 (ru) * 2021-08-26 2023-05-05 Общество с ограниченной ответственностью "Лина М" Способ реабилитации после инфаркта миокарда

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2460534A1 (en) 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
CN102170911B (zh) 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
WO2012097012A1 (en) 2011-01-10 2012-07-19 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US20150328284A1 (en) * 2012-04-02 2015-11-19 Cleveland Biolabs, Inc Compositions and methods comprising toll like receptor (tlr) stimulating agents for prophylaxis and therapy for damage to dermal epithelium
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
US10183056B2 (en) 2014-10-16 2019-01-22 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
KR20240130829A (ko) 2016-08-11 2024-08-29 템플 유니버시티 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 허혈/재관류 손상
WO2019018768A1 (en) 2017-07-20 2019-01-24 Spogen Biotech Inc. BIOACTIVE POLYPEPTIDES FOR PLANT PROTECTION, GROWTH AND PRODUCTIVITY ENHANCEMENTS
US12440536B2 (en) * 2018-05-18 2025-10-14 The University Of Hong Kong Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof
CN208752357U (zh) * 2018-09-21 2019-04-16 合肥京东方显示光源有限公司 背光模块及具有该背光模块的显示面板及显示器
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JPH05502402A (ja) 1990-09-28 1993-04-28 ゲブリユーダー　ズルツアー　アクチエンゲゼルシヤフト 医療用の中空針及びその製造方法
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
WO2001055210A2 (en) 2000-01-31 2001-08-02 Munin Corporation Human cyr61
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
WO2002044363A1 (en) 2000-11-28 2002-06-06 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
EP1379552B2 (en) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
SG176524A1 (en) 2003-12-02 2011-12-29 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
US7638485B2 (en) * 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
EP1827489B1 (en) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP2460534A1 (en) * 2004-12-22 2012-06-06 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
EP1940419A2 (en) * 2005-09-09 2008-07-09 Oregon Health and Science University Neuroprotectants
WO2007070623A2 (en) 2005-12-14 2007-06-21 Medistem Laboratories, Inc. Transcatheter tumor immunoembolization
EP2441846A3 (en) 2006-01-09 2012-07-25 The Regents Of the University of California Immunostimulatory combinations of TNFRSF, TLR, NLR, RHR, purinergic receptor, and cytokine receptor agoinsts for vaccines and tumor immunotherapy
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
CN101888856B (zh) 2007-11-07 2014-08-27 塞尔德克斯医疗公司 结合人树突和上皮细胞205(dec-205)的抗体
WO2009102818A1 (en) 2008-02-11 2009-08-20 Cleveland Biolabs, Inc. Method for reducing the effects of chemotheraphy using flagellin related polypeptides
CN102170911B (zh) * 2008-08-01 2014-07-02 克里夫兰生物实验室公司 用于治疗再灌注损伤的方法
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795656C2 (ru) * 2021-08-26 2023-05-05 Общество с ограниченной ответственностью "Лина М" Способ реабилитации после инфаркта миокарда

Also Published As

Publication number Publication date
WO2010014957A1 (en) 2010-02-04
US20110135665A1 (en) 2011-06-09
JP2011529922A (ja) 2011-12-15
CA2732763A1 (en) 2010-02-04
US20130004515A1 (en) 2013-01-03
CN102170911B (zh) 2014-07-02
AU2009276357B2 (en) 2014-09-11
US20140220037A1 (en) 2014-08-07
US8324163B2 (en) 2012-12-04
CN102170911A (zh) 2011-08-31
EP2320948A1 (en) 2011-05-18
EA201170294A1 (ru) 2011-08-30
HK1161082A1 (en) 2012-08-24
US9006180B2 (en) 2015-04-14
US8618059B2 (en) 2013-12-31
JP5577337B2 (ja) 2014-08-20
EP2320948A4 (en) 2012-01-25
AU2009276357A1 (en) 2010-02-04
EP2320948B1 (en) 2013-03-06
PT2320948E (pt) 2013-06-17
ES2412237T3 (es) 2013-07-10
US20150182587A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
EA020579B1 (ru) Способ лечения реперфузионных повреждений тканей
Kyle Amyloidosis: a convoluted story.
KR102232320B1 (ko) 장기, 조직 또는 세포 이식용 조성물, 키트 및 이식 방법
CZ285996B6 (cs) Způsob in vitro stimulace produkce nekeratinocytových epithelových buněk a růstový faktor keratinocytů pro léčbu chorob
KR100515016B1 (ko) ｐ43을 유효성분으로 하는 창상 치료용 약학적 조성물
US9884012B2 (en) Use of PEDF-derived polypeptides for promoting muscle or tendon regeneration or arteriogenesis
JP7671985B2 (ja) 細胞増殖と組織修復の促進方法及び組成物
Cai et al. Up-regulation of Thioredoxin 1 by aerobic exercise training attenuates endoplasmic reticulum stress and cardiomyocyte apoptosis following myocardial infarction
KR101736280B1 (ko) 관절염 예방 또는 치료용 약학적 조성물
US20240358795A1 (en) Fgf10 for the treatment of heart diseases
JP2001507354A (ja) 局所的モルフォゲンまたは形態形成処理された筋形成前駆体細胞による哺乳動物心筋層の処置
US8895502B2 (en) β2-glycoprotein I peptide inhibitors
Romanowicz et al. Collagen of umbilical cord vein and its alterations in pre-eclampsia.
HK1161082B (en) Methods for treating reperfusion injuries
CN115364217A (zh) Metrnl蛋白或基因在维护肠屏障中的应用
CN117265095A (zh) Asic1在制备神经病理性疼痛治疗药物中的应用
US20230390359A1 (en) Use of reelin for treating cardiac diseases
Öztürk et al. Investigation of the effects of umbilical cord-derived mesenchymal stem cells and curcumin on Achilles tendon healing–can they act synergistically?
Kato et al. Effect of epidermal growth factor on intestinal adaptation after allogeneic small bowel transplantation in rats
JP2024046128A (ja) 骨形成促進剤
Hearts 106 XXVlth Congress of the European Society for Surgical Research
Thompson et al. PROTEIN TYROSINE KINASE SUBSTRATES IN RAT INTESTINAL MICROVILLUS MEMBRANES (MVM)

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU